RIPK2 and cancer: Several studies have revealed the potential of RIPK inhibitors in amelioration of inflammatory signalling and/or inflammatory cell death, and the RIPK2 inhibitors can potently inhibited the proliferation of cancer cells (32, 34), but there are few studies that have focused on the prognostic impact of RIPK2 on lung cancer.